Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV - Wikidata - awgldk - TriplyDB

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

http://www.wikidata.org/entity/Q24681002

about

The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic Role of Marine Natural Products in the Genesis of Antiviral Agents Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir Design of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P2-Ligands: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Crystal Structure The higher barrier of darunavir and tipranavir resistance for HIV-1 protease Burkholderia oklahomensisagglutinin is a canonical two-domain OAA-family lectin: structures, carbohydrate binding and anti-HIV activity Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors Potent Antiviral HIV-1 Protease Inhibitor GRL-02031 Adapts to the Structures of Drug Resistant Mutants with Its P1′-Pyrrolidinone Ring P2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray Studies Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation Understanding the structural mechanisms of antibiotic resistance sets the platform for new discovery Proteochemometric modeling of the bioactivity spectra of HIV-1 protease inhibitors by introducing protein-ligand interaction fingerprint A Functional Interplay between Human Immunodeficiency Virus Type 1 Protease Residues 77 and 93 Involved in Differential Regulation of Precursor Autoprocessing and Mature Protease Activity Drug discovery and the use of computational approaches for infectious diseases.Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.Capturing the essence of organic synthesis: from bioactive natural products to designed molecules in today's medicine.Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.Organic carbamates in drug design and medicinal chemistry Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization Conserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes.Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.Development of anti-HIV peptides based on a viral capsid protein.Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.Experimental and computational studies on the effects of valganciclovir as an antiviral drug on calf thymus DNA.Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies Enantioselective Synthesis of Cyclopentyltetrahydrofuran (Cp-THF), an Important High-Affinity P2-Ligand for HIV-1 Protease Inhibitors.Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges.A fission yeast cell-based system for multidrug resistant HIV-1 proteases.Investigational protease inhibitors as antiretroviral therapies.Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase.Role of CXCR4 in HIV infection and its potential as a therapeutic target.Role of darunavir in the management of HIV infection.Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS

P2860

Q24655011-28331F04-7872-4C0F-B6CB-FEE2C6E4957F Q26796360-D60F030B-364F-404B-8CB5-8C54207E7337 Q27651021-A0FE9B31-A251-4FF8-A7B6-3FA99AB13628 Q27671213-FD6DE14B-5268-48A8-9E9E-BAD1CA35C05A Q27672193-221D800D-800A-4C33-86C0-6EF1C57D8DB0 Q27676767-6A23CFB7-0715-497C-92DF-6BF0CBA9961D Q27677475-6F1AB42D-E357-48C2-8ABC-60FEC5BACE27 Q27677939-DCCE89FE-9F76-48C8-80E3-174DA79E6375 Q27679177-5D19A9A4-2F0E-4E53-9697-F3599C9FCE2A Q27679692-AEB97091-00EB-4035-AE05-1099C88F9582 Q27717366-9CD0E2E9-38EC-4C4F-A874-9E4613E39B5F Q28083259-03FFF28F-36BB-4EEA-A35B-54533B0D70FF Q28481635-A79CA8C6-A977-4F39-84EB-4BD1BC27222D Q28546560-3C53CEB4-7D29-42E3-91FE-CF1191CCA4E9 Q30404272-A247FDFA-1D4A-4DB2-8367-84648A435C33 Q34046931-A519AE31-EBF8-4514-8BF6-E3BC99A12CC6 Q34361292-7DCF81B0-5138-42B3-A7D8-80187CD374DE Q34440391-734C040A-453C-48E1-8E30-C80D8418F3A2 Q34638302-E851DC29-BF88-4902-8B83-C736FE5B3227 Q35365543-0889A907-277B-4BA6-8017-133118D2DE8B Q35569236-DDFF0305-B883-4342-9C3C-91544415604C Q35846634-F7D9D7C3-4ED9-438E-A1D0-A63E0C87217E Q35903710-CE113A53-4E46-43E0-9224-12FC1F34F9C3 Q35935885-17A26584-B9D3-4317-8D25-F36D4EC0C988 Q36080284-F1748ED6-69BF-4658-92B1-448C59277958 Q36166928-35B65750-DF52-4F59-8BCA-8DC4F070CF86 Q36167461-8FB223BB-59B0-4627-A7D3-B8625B10BD36 Q36338687-14DA70C5-28A6-471E-BAB8-865EC1D2D11A Q36613697-1BC8D3F4-0DB0-4BFF-AA2D-4AA8978E369A Q36613702-EDE653C6-500E-4CB5-AD5C-3E1BB15B9D5E Q36713828-3FC6DE5B-7A7E-4D00-B554-CD7FF8FDEAEA Q37415603-49E0F93B-8F76-4ADA-A45B-9DCC6D1DE925 Q37578986-642B59DB-F33D-4B40-91AC-FEB922699097 Q37582521-C18FA1FB-1149-43CB-91DE-B2C5B329FF3F Q37644005-D02F6790-8FAF-4B4D-B8C8-9681D5B4B71C Q37772888-99864793-EA16-474A-AE06-B74B5D1D901F Q37957871-9CD948B0-7EA0-4BCA-8826-B428336AC300 Q37980084-DDFC2B5C-8DE0-4725-A034-68B3FEEA296E Q38164839-6FD7474B-AF18-4587-8CF5-F060C9A3598A Q38708006-BBC75778-7157-4CDE-95DA-112EABD12E5F

P2860

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

http://www.wikidata.org/entity/Q24681002

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@ast

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@en

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@nl

type

label

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@ast

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@en

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@nl

prefLabel

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@ast

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@en

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@nl

P1433

Q24681002-1E6F3328-A512-43A2-89B2-53C2F9AEB0F9

P1476

Q24681002-869BC8EE-ACB8-4848-ADC0-2D0C249DF6DC

P2093

Q24681002-368262C2-2B7D-4266-AC0C-5FF70A250078

Q24681002-97897065-A6D1-45F4-A82D-6489F759B972

Q24681002-BE38EAA2-F3CE-4C17-A845-736B72F85515

P2860

Q24681002-04FE1DF3-3BB4-481E-99AE-54A65DBEB4D1

Q24681002-1392E44A-5370-4971-98E2-2AF828DD1C30

Q24681002-1A0A570D-49FD-4862-A0DD-FD32F4DAB64D

Q24681002-1BEA8A1A-D025-4F8A-B770-4DC6210C5F92

Q24681002-1ED40DA5-C2A6-4E53-9DCF-5071449F3552

Q24681002-355AF026-D51D-4BE7-BBBC-31496B3D55DF

Q24681002-3BDB13BD-9C33-4AE7-BEF1-FD8C2EC33069

Q24681002-457D130F-B6CC-4232-821E-6973FAFDA1F0

Q24681002-463A4E1B-E661-4625-9502-22B4769353B6

Q24681002-5E558A7E-4603-4A3D-B1AD-B8AA6B87C131

P304

Q24681002-240F5215-8363-478F-BB07-561CCC8DF9F2

P31

Q24681002-5BCA6543-B609-4206-B004-87F55838C0EF

P356

Q24681002-F453DB61-8330-4216-8E01-F3B0B3AD09C4

P407

Q24681002-54BFE4C4-A483-438F-B556-1E0BFE147F6C

P433

Q24681002-A631A19E-44AE-4642-8017-FBB36ACDBD18

P478

Q24681002-46FECF47-FF66-4F37-B781-7FA406B61FBC

P577

Q24681002-FE3A1552-D0A1-493E-8848-7A472F7EB462

P5875

Q24681002-67A210A3-08C2-4667-8D07-B905CB40BEF4

P698

Q24681002-E0F4A6C6-6A40-45A5-8F02-93ADF3FA7B40

P921

Q24681002-BC175099-D703-4B92-8910-B1291CFF7A2F

P932

Q24681002-510CFB72-10A2-47A0-BA1A-17205EBC550F

P356

J.BMC.2007.09.010

P1433

Bioorganic & Medicinal Chemistry

P1476

Darunavir, a conceptually new ...... reatment of drug-resistant HIV

@en

P2093

Arun K Ghosh

http://www.w3.org/2001/XMLSchema#string

Hiroaki Mitsuya

http://www.w3.org/2001/XMLSchema#string

Zachary L Dawson

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)

AIDS — The First 20 Years

Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance

Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir

Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS

An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity.

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.

P304

7576-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BMC.2007.09.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5943683

http://www.w3.org/2001/XMLSchema#string

P698

17900913

http://www.w3.org/2001/XMLSchema#string

P921

P932

2112938

http://www.w3.org/2001/XMLSchema#string